If approved, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind currently on the U.S. market after Leqembi from Biogen and Eisai.
Comments
(・.・;)
There's nothing here…
If approved, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind currently on the U.S. market after Leqembi from Biogen and Eisai.